This article is more than 5 years old. Information may no longer be current.

No new treatments for gastrointestinal stromal tumors expected through 2023

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A new market report projects that the currently available treatments for gastrointestinal stromal tumors will remain unchanged throughout 2023, with no new indicated therapies expected to launch, according to a Decision Resources Group press release.

Gastrointestinal stromal tumors (GIST) are treated most commonly by surgical resection and/or targeted therapies, of which imatinib (Gleevec, Novartis) will continue to be the most commonly prescribed throughout the period forecasted, according to the release. The second-line standard of care is sunitinib (Sutent, Pfizer), which is indicated for patients with GIST who are resistant or intolerant to imatinib, and the most recently approved agent, regorafenib (Stivarga, Bayer HealthCare) is indicated for patients with progressive disease previously treated with the abovementioned agents. Regorafenib is expected to become the third-line standard of care for unresectable and/or metastatic GIST in all major markets by the end of 2023, according to the release.

Other relevant findings from the report that apply to this forecast period include a 1.3% annual increase in the incidence of GIST in major markets, an expected increase in research and development for GIST therapies, and market entry of generic versions of imatinib and sunitinib.

“Although the emerging agents are in early stages of development, interviewed experts state that the combination of emerging agents and current therapies may be the way forward in satisfying the unmet needs in GIST as they may prove more effective than monotherapies particularly for later line treatment, Kirsha Naicker, MSc, PhD, Decision Resources Group analyst, said in the release. “Interviewed experts tell us that mutational analysis is becoming increasingly important in the treatment of GIST, influencing treatment decisions based on mutational status, thereby making treatment more personalized.”